Tiefenbacher Pharmaceuticals wishes a Happy Chinese New Year!

Tiefenbacher Pharmaceuticals wishes a Happy Chinese New Year!

The Chinese New Year is almost here.On the 10th of February, people around the world celebrate the Chinese New Year. They honour this day with carnival events, family gatherings, parades, traditional…

Read More

Tiefenbacher Pharmaceuticals DKMS

Tiefenbacher Pharmaceuticals together against blood cancer

Tiefenbacher Pharmaceuticals and DKMS together against blood cancer!We are pleased to inform you that we have initiated a DKMS registration event during the last week in our headquartes in Hamburg to…

Read More

Tiefenbacher Pharmaceuticals diversity

Tiefenbacher Pharmaceuticals speaks out against racism and supports diversity

TIEFENBACHER PHARMACEUTICALS speaks out against racism and supports diversity - as a healthcare company, we are committed to stopping racism and discrimination, wherever we canTiefenbacher embraces…

Read More

Featured Video Play Icon

AET Laboratories 20th anniversary celebration

AET Laboratories 20th anniversary celebration was a tremendous success!Last year, we not only celebrated Tiefenbacher Group´s  60th anniversary in Hamburg, but also the 20th…

Read More

Featured Video Play Icon

Tiefenbacher Group wishes you a happy new year!

As 2023 draws to a close, the Tiefenbacher Group would like to share some of the year's highlights with you.This year we not only had our 60th anniversary to celebrate, but also many…

Read More

Tiefenbacher New Market Launch: Rivaroxaban in Canada

Tiefenbacher Pharmaceuticals successfully launches the anticoagulant Rivaroxaban on day one in CanadaWe at Tiefenbacher Pharmaceuticals strongly believe that our high-quality medicines should be…

Read More

Featured Video Play Icon

60 years of pioneering healthcare at Tiefenbacher Group! 

60 years of pioneering healthcare at Tiefenbacher GroupThank you to our colleagues from our three main locations in Hamburg (Germany), Hyderabad (India) and Lefkosia (Cyprus) for…

Read More

Featured Video Play Icon

Tiefenbacher Group 60 years anniversary celebration!

60 years anniversary celebrationsWe are very happy to announce that Tiefenbacher Group celebrates its 60th anniversary this year! 60 years ago, our founder and pioneer Alfred E.…

Read More

Tiefenbacher Pharmaceuticals: launch of generic Teriflunomide

New market launch: Tiefenbacher Pharmaceuticals successfully launches the generic version of Teriflunomide in more than 20 European countriesWe are thrilled to announce that we have successfully…

Read More

State-of-the-art R&D

State-of-the-art R&D facilities for powerful drug development

State-of-the-art R&D facilities for powerful drug development and manufacturing. New technology for generic, valued added, and innovative pharmaceuticalsWe, at Tiefenbacher Group, go beyond…

Read More

Featured Video Play Icon

OYSTA: NEW WEBSITE ONLINE!

OYSTA: New website online – combining pharmaceuticals with e-health technology We are happy to announce that we have launched a new web page for OYSTA – an innovative healthcare brand…

Read More

TIEFENBACHER GROUP IS COMMITTED TO BECOMING CLIMATE NEUTRAL

Tiefenbacher Group is committed to becoming climate neutral by the end of 2025We are pleased to share that TIEFENBACHER GROUP is committed to becoming climate neutral by the end of 2025*. As a…

Read More

Featured Video Play Icon

RENOVATING HEADQUARTERS IN HAMBURG

Did you know that Tiefenbacher Group is currently renovating its headquarters in Hamburg, Germany? We are excited to share the first results of the restructuring and are pleased to…

Read More

Featured Video Play Icon

TIEFENBACHER GROUP AT DCAT 2023 – THANKS FOR MEETING US IN NEW YORK CITY!

DCAT week – one of the world´s most important pharma events – has just come to an end. It was four very successful and inspiring days for TIEFENBACHER GROUP in New York City.…

Read More

New market launch: Tiefenbacher Pharmaceuticals launches antihistamine Bilastin in Germany (OTC)

New Market Launch: Tiefenbacher Pharmaceuticals successfully launches the antihistamine Bilastine for a market entry as over-the-counter (OTC) medicine in GermanyAs the allergy season is starting, we…

Read More

TIEFENBACHER GROUPS: Registration of manufacturing sites by UAE Ministry of Health

Tiefenbacher manufacturing sites have been successfully registered by the United Arab Emirates Ministry of HealthWe are excited to announce that our two manufacturing sites at AET Laboratories in…

Read More

Tiefenbacher Pharmaceuticals: World Cancer Day 2023

Tiefenbacher Pharmaceuticals marks 'World Cancer Day 2023' to increase awareness prevention throughout media togetherTIEFENBACHER joined to harness the power of social media to raise awareness on…

Read More

Featured Video Play Icon

TIEFENBACHER GROUP WISHES A HEALTHY NEW YEAR 2023

From all over the world, we wish you a happy and healthy New Year 2023! In order to serve more than 80 national markets in the best possible way for our partners, we are particularly…

Read More

TIEFENBACHER PHARMACEUTICALS new market launch: generic versions of Abiraterone/Prednisolone

Tiefenbacher Pharmaceuticals successfully launches generic versions of Abiraterone and value-added product Abiraterone/Prednisolone, Prostate CancerWe at TIEFEENBACHER PHARMACEUTICALS aim to improve…

Read More

Featured Video Play Icon

Thanks for visiting us at CPhI 2022 in Frankfurt!

CPhI 2022, the world`s leading pharma event, has just come to an end. It was wonderful to meet our valued customers and partners in person again. Our experts enjoyed three very…

Read More

Featured Video Play Icon

TIEFENBACHER GROUP opens new manufacturing site in Cyprus

Did you know that TIEFENBACHER GROUP heavily invests in its in-house production capacities? We are excited to announce that our new manufacturing site in Cyprus was ceremoniously…

Read More

Featured Video Play Icon

TIEFENBACHER GROUP AT DCAT 2022 – THANKS FOR MEETING US IN NEW YORK CITY!

One of the world´s most important pharma events – DCAT week in New York City – has just come to an end. It was four very successful and inspiring days for TIEFENBACHER GROUP…

Read More

Featured Video Play Icon

TIEFENBACHER GROUP WISHES A HAPPY AND HEALTHY NEW YEAR 2022 FROM ALL OVER THE WORLD!

We at TIEFENBACHER GROUP wish you a happy and healthy new year 2022 from all over the world! Please watch the short video for our new year greetings from our colleagues from our three…

Read More

Driving efficiency is our key – TIEFENBACHER GROUP enlarges its manufacturing facilities

Did you know that TIEFENBACHER GROUP heavily invests in its own manufacturing facilities to secure an efficient and reliable supply of our high-quality pharmaceuticals for patients around the world?…

Read More

Featured Video Play Icon

Three successful days for TIEFENBACHER GROUP at CPhI 2021 – thanks for visiting us in Milano!

With over 1,300 exhibitors and more than 20,000 attendees the world`s leading pharma event CPhI has just come to an end. It was three very successful days for TIEFENBACHER GROUP…

Read More

Featured Video Play Icon

At TIEFENBACHER GROUP giving back to society is important to us: New school building in India

As a value-driven healthcare company, dedicated to improve the life of patients worldwide, we believe that it´s our responsibility to care about the environment and society –…

Read More

TIEFENBACHER PHARMACEUTICALS at CPhI in Milan 2021

Reach out to TIEFENBACHER PHARMACEUTICALS at CPHI in Milan 2021 and discover our latest innovations to make pharmaceuticals more affordable, more available, and better than before.“Nothing can…

Read More

New market launch: TIEFENBACHER PHARMACEUTICALS successfully launches first generic version of the antihistamine Bilastine

We at TIEFEENBACHER PHARMACEUTICALS strongly believe that our high-quality medicines should be affordable for all patients irrespective of their income level or nationality. That´s why we are excited…

Read More

New agreement expands collaboration between OnDosis and TIEFENBACHER GROUP

Swedish Life science company OnDosis and German B2B pharmaceutical company TIEFENBACHER GROUP initiate four new innovative development projects targeting ADHD, rare diseases, and transplantation…

Read More

TIEFENBACHER PHARMACEUTICALS supports Post COVID-19 with Posaconazole against Black Fungus (Mucormycosis)

Black Fungus (Mucormycosis) is dramatically spreading in India connected to the extensive 2nd COVID-19 wave. The highly life-threatening disease usually occurs as a rare disease in immunocompromised…

Read More

TIEFENBACHER GROUP announces global launch of TIEFENBACHER MEDICAL DEVICES

After more than five years in operation, TIEFENBACHER GROUP will transfer its medical device business into a new stand-alone company: TIEFENBACHER MEDICAL DEVICES The launch follows TIEFENBACHER…

Read More

TIEFENBACHER PHARMACEUTICALS: Launch generic version of Teriflunomide, Multiple Sclerosis (MS)

Tiefenbacher Pharmaceuticals announces global launch of Teriflunomide – making multiple sclerosis therapy more affordable and better available worldwideTiefenbacher Pharmaceuticals has successfully…

Read More

AET Pharma US Inc., Part of Tiefenbacher, approval of Abbreviated New Drug Application (ANDA) for Posaconazole

AET Pharma US Inc., a part of TIEFENBACHER GROUP, announces successful approval of Abbreviated New Drug Application (ANDA) for PosaconazoleOn 1st February 2021, AET Pharma US Inc, part of…

Read More

TIEFENBACHER PHARMACEUTICALS: Launch of Rivaroxaban – an anticoagulant medication (blood thinner)

TIEFENBACHER PHARMACEUTICALS, part of Tiefenbacher Group, is pleased to announce the availability of a registration dossier for the generic of Rivaroxaban 2.5 mg, 10 mg, 15 mg and 20 mg film-coated…

Read More

International Brand Relaunch of TIEFENBACHER PHARMACEUTICALS

AET TIEFENBACHER PHARMACEUTICALS: Making pharmaceuticals more affordable, more affordable, and better than before“We are very excited to launch our new AET website, representing the pharmaceutical…

Read More

Tiefenbacher Group and OnDosis enter a strategic partnership for game-changing integration of medicines and digital health

Tiefenbacher Group and OnDosis today announced the signing of an extensive co-development agreement for multiple products in the upcoming years. This collaboration strengthens both companies’…

Read More